Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP, Chief Commercial Officer

Founder, President, and CEO

Chief Medical Officer

EVP & Chief Scientific Officer

Chief Financial Officer

Chief Legal Officer

Interim CEO

Interim CFO

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promo...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	-
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	-
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	EVP, Chief Commercial Officer
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	-
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	Founder, President, and CEO
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	-
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	Chief Medical Officer
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	-
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	-
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	-
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	EVP & Chief Scientific Officer
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	-
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	-
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	Chief Financial Officer
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	Chief Legal Officer
2024-01-23	Premium	back to issuer	Premium	Premium	Premium	-
2024-01-16	Premium	sold	Premium	Premium	Premium	EVP, Chief Commercial Officer
2024-01-16	Premium	sold	Premium	Premium	Premium	EVP & Chief Scientific Officer
2024-01-08	Premium	sold	Premium	Premium	Premium	EVP, Chief Commercial Officer
2024-01-04	Premium	sold	Premium	Premium	Premium	EVP & Chief Scientific Officer
2023-12-29	Premium	acquired	Premium	Premium	Premium	-
2023-12-29	Premium	acquired	Premium	Premium	Premium	-
2023-12-29	Premium	acquired	Premium	Premium	Premium	EVP, Chief Commercial Officer
2023-12-29	Premium	acquired	Premium	Premium	Premium	-
2023-12-29	Premium	acquired	Premium	Premium	Premium	Interim CEO

MRTX - Mirati Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for MRTX